Company Description

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs. We believe that we are well positioned to compete successfully in these areas using our proprietary siRNA technology platform and immunotherapy agent, Samcyprone™. The Company is supported by a proven and experienced management team, an accomplished Scientific Advisory Board and an extensive intellectual property portfolio.


Officers and Directors
Management Team
   Geert Cauwenbergh, Dr. Med. Sc.
President and Chief Executive Officer
   Alexey Eliseev, Ph.D.
Chief Business Officer
   Gerrit Dispersyn, Dr. Med. Sc.
Chief Development Officer
   Karen Bulock, Ph.D.
Vice President Research
 
Board of Directors
   Robert Bitterman
Chairman
   Keith Brownlie
   Geert Cauwenbergh, Dr. Med. Sc.
   H. Paul Dorman
   Curtis Lockshin, Ph.D.
 
Scientific Advisory Board
   Craig C. Mello, Ph.D.
Chairman
   Peter Campochiaro, M.D.
   Jeannette Graf, M.D.
   James D. Griffin, M.D.
   Rolf Kiessling, M.D.
   Pamela Pavco, Ph.D.
   Leroy Young, M.D.
 
 
Recent Documents

Filing DescriptionFiling TypeFiling DateEvent Date
8-K8-K5/11/20175/11/2017
10-Q10-Q5/11/20173/31/2017
Registration StatementPOS AM5/4/2017
8-K8-K5/1/20174/29/2017
ProxyDEF 14A4/27/20176/6/2017
FAQ
No data available.